Imodium and Xopenex hfa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imodium (loperamide hydrochloride) and Xopenex hfa (levalbuterol tartrate). Common drug interactions include drug ineffective among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Imodium and Xopenex hfa. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Imodium?

Imodium has active ingredients of loperamide hydrochloride. It is often used in diarrhea. eHealthMe is studying from 45,092 Imodium users. Check the latest studies of Imodium.

What is Xopenex hfa?

Xopenex hfa has active ingredients of levalbuterol tartrate. It is often used in asthma. eHealthMe is studying from 2,529 Xopenex hfa users. Check the latest studies of Xopenex hfa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 20, 2026

19 people who take Imodium and Xopenex hfa together, and have interactions are studied.

Imodium and Xopenex hfa drug interactions.

What are the common drug interactions of Imodium and Xopenex Hfa, by gender? *:

female:

  1. Drug ineffective
  2. Dysphonia (speech disorder attributable to a disorder of phonation)
  3. Injection site pain
  4. Pulmonary oedema (fluid accumulation in the lungs)
  5. Weight decreased
  6. Oedema peripheral (superficial swelling)
  7. Pain in extremity
  8. Pneumonia
  9. Staphylococcal infection (an infection with staphylococcus bacteria)
  10. Blood pressure fluctuation

male:

  1. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  2. Nausea (feeling of having an urge to vomit)
  3. Vomiting
  4. Injection site pain
  5. Pain
  6. Pain of skin
  7. Sleep disorder

What are the common drug interactions of Imodium and Xopenex Hfa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  2. Nausea (feeling of having an urge to vomit)
  3. Vomiting

30-39:

n/a

40-49:

n/a

50-59:

  1. Injection site erythema (redness at injection site)
  2. Injection site pruritus (severe itching at injection site)
  3. Injection site rash
  4. Nausea (feeling of having an urge to vomit)
  5. Vomiting

60+:

  1. Oedema peripheral (superficial swelling)
  2. Pain in extremity
  3. Abdominal pain
  4. Abdominal wall haematoma (abdominal wall blood clotting)
  5. Anaemia (lack of blood)
  6. Anaemia of chronic disease
  7. Aspartate aminotransferase increased
  8. Atelectasis (partial or complete collapse of the lung)
  9. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  10. Back pain

What are the existing conditions these people have? *

  1. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 5 people, 26.32%
  2. Restless Leg Syndrome (a powerful urge to move your legs): 5 people, 26.32%
  3. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 15.79%
  4. Irritable Bowel Syndrome: 3 people, 15.79%
  5. Drowsiness: 3 people, 15.79%
  6. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 15.79%
  7. Nausea (feeling of having an urge to vomit): 2 people, 10.53%
  8. Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 2 people, 10.53%
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 2 people, 10.53%
  10. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Imodium and Xopenex hfa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Imodium and Xopenex hfa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Xopenex hfa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Imodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xopenex hfa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on loperamide hydrochloride and levalbuterol tartrate (the active ingredients of Imodium and Xopenex hfa, respectively), and Imodium and Xopenex hfa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: